PMID- 8572785
OWN - NLM
STAT- MEDLINE
DCOM- 19960306
LR  - 20190628
IS  - 0003-4975 (Print)
IS  - 0003-4975 (Linking)
VI  - 61
IP  - 2
DP  - 1996 Feb
TI  - Retention of endothelium-dependent properties in human mammary arteries after 
      cryopreservation.
PG  - 667-73
AB  - BACKGROUND: We investigated the effects of cryopreservation and antibiotic 
      treatment on endothelium-dependent vasomotor properties of human internal mammary 
      arteries (IMAs). METHODS: Sixty IMA specimens from routine coronary artery bypass 
      grafting procedures were randomly assigned to six groups. Group I (controls) were 
      immediately tested after harvest. Remaining groups were prepared according to a 
      stepwise design: group II, 6 hours of warm ischemia; group III, 6 hours of warm 
      ischemia + 24 hours at 4 degrees C (without antibiotics); group IV, 6 hours of 
      warm ischemia + 24 hours of 4 degrees C antibiotic disinfection; group V, 6 hours 
      of warm ischemia + 24 hours at 4 degrees C (without antibiotics) + 
      cryopreservation; and group VI, 6 hours of warm ischemia + 24 hours of 4 degrees 
      C disinfection+cryopreservation. The IMA specimens were cut into rings and the 
      tension of vascular smooth muscle was recorded. The IMA rings were contracted 
      with norepinephrine (3 x 10(-6) mol/L) and tested with cumulative concentrations 
      of acetylcholine (from 1 x 10(-9) to 1 x 10(-5) mol/L), contracted with 
      endothelin-1 (from 1 x 10(-11) to 1 x 10(-6) mol/L), and contracted with the 
      nitric oxide-synthase inhibitor NG-monomethyl-L-arginine (1 x 10(-4) mol/L). 
      Rings were also tested for their capacity to generate 6-keto-prostaglandin F1 
      (the stable metabolite of prostacyclin), and endothelial cell viability rate was 
      finally evaluated with the trypan blue dye exclusion method. RESULTS: Our results 
      show that a complete cryopreservation protocol does not significantly modify (p > 
      0.05) the relaxant activity to acetylcholine in norepinephrine-precontracted IMA 
      rings (controls; 90.2% +/- 4.2% vs group VI, 77.1% +/- 6.2%) or the 
      vasoconstrictor response induced by endothelin-1 (controls, 62.6% +/- 2.8% versus 
      group VI, 73.7% +/- 4.8%) and NG-monomethyl-L-arginine (controls, 22.4% +/- 1.5% 
      versus group VI, 18.9% +/- 1.9%). Furthermore, IMA cryopreservation does not 
      significantly modify (p > 0.05) the endothelial release of prostacyclin either in 
      basal conditions (-20% versus controls) or during pharmacologic intervention with 
      acetylcholine (-18% versus controls), endothelin-1 (-17% versus controls), and 
      NG-monomethyl-L-arginine (-18% versus controls). CONCLUSIONS: We conclude that 
      the IMA endothelial function does not seem significantly injured by any of the 
      current steps of disinfection and cryopreservation.
FAU - Pompilio, G
AU  - Pompilio G
AD  - Department of Cardiac Surgery, Italian Homograft Bank, Milan, Italy.
FAU - Polvani, G L
AU  - Polvani GL
FAU - Antona, C
AU  - Antona C
FAU - Rossoni, G
AU  - Rossoni G
FAU - Guarino, A
AU  - Guarino A
FAU - Porqueddu, M
AU  - Porqueddu M
FAU - Buche, M
AU  - Buche M
FAU - Biglioli, P
AU  - Biglioli P
FAU - Sala, A
AU  - Sala A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Endothelins)
RN  - 0 (Vasoconstrictor Agents)
RN  - 27JT06E6GR (omega-N-Methylarginine)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - 94ZLA3W45F (Arginine)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - N9YNS0M02X (Acetylcholine)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/metabolism
MH  - Acetylcholine/pharmacology
MH  - Analysis of Variance
MH  - Anti-Bacterial Agents/pharmacology
MH  - Arginine/analogs & derivatives/pharmacology
MH  - *Cryopreservation
MH  - Dose-Response Relationship, Drug
MH  - Endothelins/pharmacology
MH  - Endothelium, Vascular/drug effects/*physiopathology
MH  - Humans
MH  - In Vitro Techniques
MH  - Mammary Arteries/drug effects/*physiopathology
MH  - Muscle, Smooth, Vascular/drug effects
MH  - Nitric Oxide Synthase/antagonists & inhibitors
MH  - Norepinephrine/pharmacology
MH  - Vasoconstriction/drug effects
MH  - Vasoconstrictor Agents/pharmacology
MH  - Vasodilation/drug effects
MH  - omega-N-Methylarginine
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
AID - 0003-4975(95)01090-4 [pii]
AID - 10.1016/0003-4975(95)01090-4 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 1996 Feb;61(2):667-73. doi: 10.1016/0003-4975(95)01090-4.